%PDF-1.6
%
Save time and jump to the most important pieces.
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
4 - Avalon GloboCare Corp. (0001630212) (Issuer)
8-K - Avalon GloboCare Corp. (0001630212) (Filer)
10-Q - Avalon GloboCare Corp. (0001630212) (Filer)
8-K - Avalon GloboCare Corp. (0001630212) (Filer)
SC 13D/A - Avalon GloboCare Corp. (0001630212) (Subject)
Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 Symbol Change Better Reflects Avalon's New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from "AVCO" to "ALBT" at the open of market trading on Thursday, November 10, 2022. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "Yesterday we announced a transformative acquisition of Laboratory Services MSO, LLC,
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company")(NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentation details:Event:LD Micro Main Event XVDate:Wednesday, October 26th, 2022Time:4:00 PM PT/ 7:00 PM ET Register to watch the virtual presentation here.Management will be available for one-on-one meetings
Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematol
VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today announces the appointment of Peter Goldstein, currently a Siyata Board member, as the Chairman of its Board of Directors. In addition, Luisa Ingargiola, who has extensive experience on public company boards and in the capital markets, has been appointed to the Board of Directors effective as of the shareholders meeting on February 23, 2021. “Peter’s many years in working with emerging growth, publicly traded companies is paramount to our asking him to